Infection
Our strategic objective
We aim to build a leading franchise in the treatment of infectious diseases through continued commercialisation of the in-line brands such as Synagis, Merrem and FluMist, effective use of our structural and genomic-based discovery technologies and antibody platforms, and through continued research of novel approaches in areas of unmet medical need.
- Merrem sales of $897 million, up 13%.
- Strong reported growth for Merrem of 16% globally; 39% in the US.
- Synagis sales of $1.23 billion; in the US $923 million.
- Biologics Licence Application submitted for motavizumab, an improved anti-respiratory syncytial virus monoclonal antibody. A Complete Response Letter subsequently received from the FDA.
- Market authorisation application submitted to European Medicines Agency for Live Attenuated Influenza Vaccine.
Synagis (palivizumab) is a humanised monoclonal antibody used for the prevention of serious lower respiratory tract disease caused by RSV in paediatric patients at high risk of acquiring RSV disease.
Merrem/Meronem1 (meropenem) is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients.
FluMist (Influenza Virus Vaccine Live, Intranasal) is a live, attenuated, trivalent influenza virus vaccine licensed in the US for active immunisation of people two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
1Licensed from Dainippon Sumitomo Pharma Co., Ltd.
THERAPY AREA WORLD MARKET (MAT/Q3/08)
The world Infection market is valued at $77 billion, with anti-bacterials accounting for approximately 46% and anti-virals for 25%.
World demand for antibiotics remains high, due to escalating resistance and the increased risk of serious infections in both immuno-suppressed patients and ageing populations. Approximately half of all infants are infected with RSV during the first year of life. Seasonal influenza results in three to five million cases of severe illness and up to half a million deaths globally each year.
QUICK LINKS
DOWNLOAD REPORT
Our report is available to download in GLOSSARY
Abbreviations/expressions and their meanings, when used on this website
CORPORATE RESPONSIBILITY
Find out more about our commitment to responsible business
FEEDBACK
Your opinions and comments are very important to us
